Clinical Trials
3 trialsNCT02643303 2022-12-02
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT02549651 2019-02-27
MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)
MedImmune LLC
Phase 1 Completed
NCT02205333 2017-06-28
MEDI6469
MedImmune LLC
Phase 1/2 Terminated